<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00744666</url>
  </required_header>
  <id_info>
    <org_study_id>07142008</org_study_id>
    <nct_id>NCT00744666</nct_id>
  </id_info>
  <brief_title>IntraVitreal Triamcinolone Acetonide: Preventing Raised Eye-pressure by Tracking Elevations After Topical Steroids</brief_title>
  <acronym>IVTA:PRE-TREAT</acronym>
  <official_title>IntraVitreal Triamcinolone Acetonide: Preventing Raised Eye-pressure by Tracking Elevations After Topical Steroids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hotel Dieu Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hotel Dieu Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intravitreal triamcinolone acetonide (IVTA) is a commonly employed treatment for various
      vitreoretinal disorders. However, approximately 23% to 50% of patients who receive IVTA
      develop ocular hypertension after the drug is injected into the eye. Similar to IVTA,
      topically administered corticosteroids eye drops result in ocular hypertension in
      approximately 33% of the population. It is unknown whether identifying patients who develop
      ocular hypertension from topical corticosteroids could be used to identify patients who are
      at risk for injectable IVTA. Therefore, the purpose of this study is to evaluate the efficacy
      of topical prednisolone 1% four times daily for one month as a screening test to reduce the
      incidence and severity of ocular hypertension after IVTA injection.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2008</start_date>
  <completion_date type="Anticipated">July 2010</completion_date>
  <primary_completion_date type="Anticipated">June 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To detect a 60% or greater decrease of developing ocular hypertension (&gt;20 mmHg) in the group of patients who received a trial of prednisolone 1% gtts x 4 weeks, compared the group who did not receive a trial of topical prednisolone.</measure>
    <time_frame>Monthly for 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Acuity</measure>
    <time_frame>Monthly for 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of other complications (cataract, retinal detachment, endophthalmitis)</measure>
    <time_frame>Monthly for 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Vitreoretinal Disease</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive Prednisolone 1% 1gtt qid x 4 weeks. If the intraocular pressure (IOP) after the 4 weeks is &gt; or equal to 21 mmHg, then IVTA will be withheld. If the IOP &lt; 21mmHg, then patients will receive an injection of IVTA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will receive an injection of IVTA (no trial of Prednisolone gtts is given).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone 1% topical eye drops</intervention_name>
    <description>Prednisolone 1% 1gtt qid to the eye requiring IVTA</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed with vitreoretinal disease for which IVTA has been chosen as
             treatment

        Exclusion Criteria:

          -  &lt; 18 years old

          -  Pregnancy

          -  Breast feeding

          -  hx of uveitis

          -  hx of neovascularization of the iris or anterior chamber angle

          -  hx of ocular herpes simplex keratitis

          -  hx of glaucoma

          -  Unable to provide informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth Eng, MD, FRCSC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Health Sciences Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeffery Gale, MD, FRCSC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hotel Dieu Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kenneth Eng, MD, FRCSC</last_name>
    <phone>416-480-4468</phone>
    <email>kt_eng@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeffery Gale, MD, FRCSC</last_name>
    <phone>613-544-3400</phone>
    <phone_ext>3391</phone_ext>
    <email>jeffgaleuwo@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hotel Dieu Hospital</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 5G2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffery Gale, MD, FRCSC</last_name>
      <phone>613-544-3400</phone>
      <phone_ext>3391</phone_ext>
      <email>jeffgaleuwo@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Christina Leung, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeffery Gale, MD, FRCSC</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Delan Jinapriya, MD, FRCSC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bernard Hurley, MD, FRCSC</last_name>
      <phone>(613) 737-8899</phone>
      <phone_ext>79422</phone_ext>
      <email>bhurley@Ottawahospital.on.ca</email>
    </contact>
    <investigator>
      <last_name>Bernard Hurley, MD, FRCSC</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sylvia Chen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth Eng, MD, FRCSC</last_name>
      <phone>416-480-4688</phone>
      <email>kt_eng@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Peter Kertes, MD, FRCSC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carol Schwartz, MD, FRCSC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Weisbrod, MD, FRCSC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kenneth Eng, MD, FRCSC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brent Michael, MD, FRCSC</last_name>
      <phone>416-603-5444</phone>
      <email>mh.brent@utoronto.ca</email>
    </contact>
    <investigator>
      <last_name>Michael Brent, MD, FRCSC</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chirag Shah, MD, FRCSC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrick Santiago, MD, FRCSC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Jonas JB, Kreissig I, Degenring R. Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol. 2003 Jan;87(1):24-7.</citation>
    <PMID>12488256</PMID>
  </reference>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 29, 2008</study_first_submitted>
  <study_first_submitted_qc>August 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2008</study_first_posted>
  <last_update_submitted>August 4, 2009</last_update_submitted>
  <last_update_submitted_qc>August 4, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 6, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr. Kenneth Eng</name_title>
    <organization>Sunnybrook Health Sciences Centre</organization>
  </responsible_party>
  <keyword>Intravitreal triamcinolone acetonide</keyword>
  <keyword>Side-effects</keyword>
  <keyword>Ocular hypertension</keyword>
  <keyword>Glaucoma</keyword>
  <keyword>Prevention</keyword>
  <keyword>Vitreoretinal diseases requiring IVTA for treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

